| REVIEW ARTICLE |
|
| Year : 2009 | Volume
: 5
| Issue : 9 | Page : 16-20 |
|
|
Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors
Seema Gupta1, Abdullah Farooque2, JS Adhikari2, Saurabh Singh2, BS Dwarakanath2
1 Division of Radiation Biosciences, Institute of Nuclear Medicine and Allied Sciences, New Delhi, India; Department of Radiation Oncology, Sylvester Comprehensive Cancer Centre University of Miami, FL/USA
2 Division of Radiation Biosciences, Institute of Nuclear Medicine and Allied Sciences, New Delhi, India
Correspondence Address:
B S Dwarakanath
Institute of Nuclear Medicine and Allied Sciences, New Delhi - 110 054, India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-1482.55135
|
|
|
The development of an approach based on the energy-linked modification of DNA repair and cellular recovery processes using 2-deoxy-D-glucose (2-DG; inhibitor of glycolytic ATP production) has shown promising results in a number of model systems of cancer. Following encouraging results on the tolerance and toxicity (acute as well as late effects) of the combination (2-DG and hypofractionated radiotherapy) in Phase I and II clinical trials, its efficacy is currently under evaluation in Phase III clinical trials for glioma patients. Since heterogeneous physiologic and metabolic status in tumors as well as host-tumor interactions influence the local tumor control, which coupled with systemic disturbances could determine the cure (long-term tumor free survival), investigations on the in vivo responses of tumors to the combined treatment have received considerable attention. This communication provides a brief overview on the in vivo studies related to radio- and chemosensitization of tumors by 2-DG, besides the normal tissue toxicity induced by the combined treatment of 2-DG and radiation or chemotherapeutic drugs. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
